Financial insights of TECX

MyFinsight

Tectonic Therapeutic, Inc. (TECX)

Income Statement	2026-03-31	2025-12-31
Research and development	NaN	-21,204*
General and administrative	NaN	5,137*
Total operating expenses	NaN	-16,067
Loss from operations	NaN	16,067*
Research and development expense-Employee Related Expenses	-4,119	NaN
Interest income	NaN	2,825*
General and administrative expense-Employee Related Expenses	-1,755	NaN
Interest expense	NaN	16*
Research and development expense-Research And Pre-Clinical Expenses	-1,578	NaN
Change in fair value of safe liabilities	NaN	0*
Research and development expense-Clinical And Development Expenses	-9,664	NaN
Other expense	NaN	-30*
Research and development expense-Chemistry Manufacturing And Control Expenses	-3,518	NaN
Total other income, net	NaN	2,779*
Research and development expense-Non-Clinical Science Expenses	-314	NaN
Loss before income tax	NaN	18,846*
Non-controllable expenses	-2,822	NaN
Income tax expense	NaN	308*
Other income	-1,471	NaN
Net loss	-25,241	18,538

Basic EPS	-1.34	-1.012
Diluted EPS	-1.34	-1.012
Basic Average Shares	18,769,004	18,322,533
Diluted Average Shares	18,769,004	18,322,533

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.